• We Continued toExpand the DehydraTECH Licensee Eco-System, As Leading Multi-StateOperator MariMed Inc. Launched New DehydraTECH-Powered Products inQ2

• DehydraTECHLicensee 1906 Launched an Exciting New Direct-To-Consumer ProductLine, Produced Using DehydraTECH, Across A Majority of US StatesDuring Q2, Adding to Their Existing Product Lines Already Sold inLicensed Dispensaries

• We Continued toDrive Marketplace Growth on Vin(Zero) Alcohol-Free Wine, IncreasingShipments to Retailers by 11% in Q2 vs. Year Ago and Adding theLargest Grocery Retailer in Western Canada – Save-On-Foods – to OurBase of Vin(Zero) Customers

FINANCIAL HIGHLIGHTS FOR Q2 FY 2024AND THE SIX MONTHS ENDED DECEMBER 31, 2023

• We Delivered theSecond-Highest Quarterly Gross Profit in Company History in Q2,Topping $500K For the Second Time

• We Narrowed theNet Loss for the Six-Month Period by 23% vs. Same Period YearAgo

Toronto, ON. – TheNewswire – March 1, 2024 — Hill Incorporated,formerly Hill Street Beverage Company Inc. ( TSXV:HILL ) ( OTC:HSEEF )(” Hill ” or the ” Company “), is pleased to announce that ithas released its financial results for the three- and six-monthperiods ended December 31, 2023 (“ Q2 ”), which can befound at www.sedarplus.com .  Theprogressive bioscience implementation company is dedicated to buildingpathways to better and healthier living by leveraging deep CPGexpertise to commercialize leading-edge technologies, craftingsuperior cannabis solutions and non-alcoholic beverage productsglobally. The financial information summarized in this press releaseis based on data from Q2 FY2024.

We Continued to Expand theDehydraTECH Licensee Eco-System, As Leading Multi-State OperatorMariMed Inc. Launched New DehydraTECH-Powered Products in Q2 Intensive R&D, product and commercial manufacturingdevelopment led to our November 16, 2023 announcement that leadingmulti-state operator MariMed will use the patented DehydraTECHbiodelivery technology to power the next generation of cannabisedibles sold under several of its award-winning brands.

MariMed has now rolled out improved DehydraTECH-poweredproducts in Massachusetts, Maryland, andDelaware, with Illinois planned to launch in early 2024 aswell. MariMed brands now powered byDehydraTECH include ‘ Vibations ’ all-natural,full-spectrum cannabis drink mix, which recently won first place inthe beverages category of the High Times CannabisCup in Massachusetts, ‘ K Fusion ’ chewable tablets, and ‘ InHouse TM ’ gummies. More information on MariMedbrands can be found at MariMedBrands .

We anticipate that this major new multi-state,multi-brand licensee will deliver strong incremental licensingrevenues in 2024 as their launches reach full scale and expand acrosstheir state footprint.

The addition of MariMed to our DehydraTECH licenseeecosystem represents continued expansion by Hill on the key factorsdriving the growth agenda of our DehydraTECH licensing business:

1) new licensees –increasing our base of active licensees and brands;

2) new states – newstate launches expanding the geographic coverage for active licenseesor brands;

3) new product form factors – innovation to expand the number of DehydraTECH-poweredconsumer product forms and types in market tofill consumer needs and occasions; and

4) deeper penetration of products acrossoperations – driving deeper penetration of thebreadth of product forms and brands across current and newstates.

The following chart shows the significant advances wehave made in the DehydraTECH licensing business, beginning from theDecember 2020 rights acquisition through December 2023 at the close ofQ2 FY 2024.

DehydraTECH Licensee 1906 Launched anExciting New Direct-To-Consumer Product Line, Produced UsingDehydraTECH, Across A Majority of US States During Q2, Adding to TheirExisting Product Lines Already Sold in Licensed Dispensaries

1906 also launched an exciting new direct-to-consumer(DTC) product line across a majority of US states, offeringhemp-derived Delta-9 THC micro-dose versions of their popular‘Drops’ products, which are also produced using DehydraTECH. This DTC launch expanded access of 1906 Drops varieties to a muchbroader footprint of consumers, adding DTC distribution acrossapproximately 36 states.  This new initiative adds to the dispensaryavailability in several legal adult-use states of the higher dose,marijuana-derived delta-9 THC 1906 Drops.  1906 has announced thatthey will be streamlining the dispensary availability of the higherdose, marijuana-derived delta-9 THC 1906 Drops to Illinois,Massachusetts, Missouri, New Jersey, New York and Pennsylvania. Moreinformation on 1906’s products can be found at https://1906.shop/.

We Continued to Drive MarketplaceGrowth on Vin(Zero) Alcohol-Free Wine, Increasing Shipments toRetailers by 11%  in Q2 vs. Year Ago and Adding the Largest GroceryRetailer in Western Canada – Save-On-Foods – to Our Base of Vin(Zero)Customers

As communicated, the new streamlined commercial modelon our alcohol-free business creates a new and different cadence tothe business, where dramatic quarter-to-quarter swings on therecognized revenues are planned based on inventory efficiencies. Therefore, the business must be looked at across longer time framesand through different operational lenses.  As we adapt to the newcadence of supply shipments and recognized revenues, a key measure ofthe underlying business in this new model is our case depletions,which represents the shipment figures from our distributor toretailers.  Our shipments from warehouses to retail customersincreased by a strong 11% during the quarter vs. year ago, showingstrength of support for the 2023 holiday period.

In addition, we secured a major new account during theperiod that added to the strong shipments to retail, addingSave-On-Foods to our customer base.  Save-On-Foods is WesternCanada’s largest grocery retailer 1 , with a dynamic history dating back to 1915.  TheirWholesale Division also services ChoiceMarkets , Quality Foods , Georgia Main , AG Foods , Buy-LowFoods & CalgaryCo-Op .  In total, this placement provides newconsumer access to Vin(Zero) through approximately 165 Save-On-Foodsstores across British Columbia , Alberta , Saskatchewan , Manitoba and the YukonTerritory .  We are excited about this newadditional business and its impact in 2024, on top of our strongexisting base of customers.

We Delivered the Second-HighestQuarterly Gross Profit in Company History, Topping $500K for theSecond Time

Consolidated net revenue for Q2 was a very strong$982,773 – the third highest ever – and our Q2 gross profit of$537,218 was the second highest in history, trailing only the recordQ2 year ago.  The year ago quarter had extraordinarily high revenuesfor the Company due to significant inventory building on thealcohol-free wine business for the first winter of the new businessmodel.  Our subsequently improved forecasting and inventoryefficiency planning, as we’ve executed themodel, resulted in a less significant inventorybuild-up for this winter season; however, alcohol-free wine netrevenue in Q2 was still a very strong $671,201.

We Narrowed the Net Loss for theSix-Month Period by 23% vs. Same Period Year Ago

As reported, gross profit of $537,218 was the secondhighest level reached in company history, trailing only the recordyear ago Q2. Yet, on a consolidated basis, gross profit declined 30%for the six-month period vs. year ago that included the record Q2. As discussed, the variance is due to the changes in alcohol-freewine inventory buildup and resulting recognized revenue between thetwo years. Despite this decline in consolidated revenue and grossprofit for the six-month period, the significant cost reductionmeasures we have taken have resulted in the net loss for the periodimproving a full 23% vs. year ago, decreasing from $856,925 to$650,614.

For the Company’s full financial statements and acomprehensive Company update by way of its Management Discussion andAnalysis, please visit the Company’s profile at www.sedarplus.com .

Company Returns to OTC PinkMarkets

On or around March 1, 2024, the Company’s stock willreturn to the OTC Pink Market from the OTCQB Venture Market(“OTCQB”) where its shares are currently traded.  In the pastyear since we listed on the OTCQB, we have observed that there isminimal trading volume on that marketplace of the Company’s commonshares.  As a result, we believe that the value in maintaining itsOTCQB listing does not substantiate the cost.  The ticker symbol willbe unchanged and investors will still be able to purchase Hill commonshares via its OTC Pink listing in the United States (under the symbol“HSEEF”) or under its TSX-V listing in Canada (under the symbol“HILL”).

About Hill Incorporated (TSXV: HILL)/ (OTCQB: HSEEF)

Hill Incorporated is a progressive bioscienceimplementation company that is dedicated to building pathways tobetter and healthier living by leveraging our deep CPG expertise tocommercialize leading-edge technologies to craft superior cannabissolutions and non-alcoholic beverage products globally. Our HillAvenue Cannabis business unit is pioneering the space where craftconsumer products meet bioscience by combining our deep CPGcommercialization expertise with our rights to use LexariaBioscience Corp’s ground-breaking DehydraTECH patentportfolio for product development, licensing and B2B and B2C salesof cannabis ingredients or products on a global scale. Our Hill StreetBeverages business unit represents theCompany’s legacy alcohol-free consumer beverage marketing anddistribution business.

For more information on our business activities visit www.hillincorporated.com , tolearn more about our DehydraTECH cannabis biodelivery technology, goto www.dehydratech-thc.com , orto check out Hill Street Beverage’s award-winning alcohol-free wineline-up and order product to be delivered straight to your home, go to www.hillstreetbeverages.com .

If you wish to sign up for the Hill Incorporatedmailing list, click HERE .

For more information, contact:

Craig Binkley, Chief Executive Officer

Email: craig@hillincorporated.com

Phone: 604-609-6154

FORWARD-LOOKING STATEMENTS

Statements in this press release may containforward-looking information. Any statements in this press release thatare not statements of historical fact may be deemed to beforward-looking statements. Forward-looking statements are oftenidentified by terms such as “may”, “should”, “would”,“anticipate”, “expects”, and similar expressions. The readeris cautioned that assumptions used in the preparation of anyforward-looking information may prove to be incorrect. Events orcircumstances, such as future availability of capital on favourableterms, may cause actual results to differ materially from thosepredicted, as a result of numerous known and unknown risks,uncertainties, and other factors, many of which are beyond the controlof the Company. The reader is cautioned not to place undue reliance onany forward-looking information. Such information, although consideredreasonable by management at the time of preparation, may prove to beincorrect and actual results may differ materially from thoseanticipated. Forward-looking statements contained in this pressrelease are expressly qualified by this cautionary statement. Theforward-looking statements contained in this press release are made asof the date of this press release. The Company does not undertake anyobligation to update publicly or to revise any of the includedforward-looking statements, whether as a result of new information,future events or otherwise, except as required by securitieslaw.

Neither TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

1 Source:Save-On-Foods

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• In a multi-year deal, MariMed licenses DehydraTECH to power new and improved versions of products under their top-selling cannabis edibles brands ‘Vibations’ hydrating drink mix and ‘K Fusion’ chewable tablets, with additional brands and new products expected to follow.

• MariMed’s DehydraTECH-powered fast-acting products are expected to hit shelves in Massachusetts, Maryland, Illinois, and Delaware in the coming months.

Toronto, ON. – TheNewswire – November 16, 2023 — Hill Incorporated, formerly Hill Street Beverage Company Inc. (TSXV:HILL) (OTC:HSEEF) (“Hill” or the “Company”), is pleased to announce that on November 3,  2023,  its DehydraTECH commercialization partner Dehydr8, LLC (“Dehydr8”) executed  a new definitive multi-year sublicensing deal with leading multi-state cannabis operator MariMed Inc. (“MariMed”), for an initial term ending June 30, 2026, with an option to renew for an additional 5 years.

MariMed will use the patented DehydraTECH biodelivery technology to power the next generation of cannabis edibles sold under several of its award-winning brands.   These new and improved versions of MariMed products were precisely developed and tested to deliver better efficacy, speed of onset, consistency, and taste.  Product innovation using DehydraTECH has also enabled MariMed to create products that meet a wider range of consumer needs and taste profiles.

Craig Binkley, CEO, comments: “We want to recognize the Dehydr8 team for their tireless efforts in completing the intensive R&D and product development efforts with the exceptional MariMed team, culminating in today’s announcement that DehydraTECH has been selected by another industry trailblazer committed to delivering the highest-quality and most effective cannabis products to consumers.   Hill continues to work very closely with the Dehydr8 team to develop relationships and commercial manufacturing operations for DehydraTECH with companies and brands that are bringing proven CPG philosophies and practices to the cannabis market.  I congratulate both partners for their commitment to quality and innovation and look forward to consumers getting the benefits of DehydraTECH product improvement in the strong MariMed brands that they love.”

Over the next few months, MariMed will roll out the improved DehydraTECH products, including ‘Vibations’ all-natural, full-spectrum cannabis drink mix and ‘K Fusion’ chewable tablets, in Massachusetts, Maryland, Illinois, and Delaware.

Today’s announcement represents continued expansion by Hill on the key factors driving the growth agenda of its DehydraTECH licensing business, as detailed in the Company’s October 24, 2023 Management’s Discussion & Analysis.   The following chart shows the significant advances we have made year-over-year in the DehydraTECH licensing business, beginning from the December 2020 rights acquisition through December 2023 (expected).

About MariMed (CSE: MRMD) (OTCQX: MRMD)

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, InHouse, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations, which are trademarks of MariMed Inc.  For additional information, visit www.marimedinc.com.

About Hill Incorporated (TSXV: HILL) / (OTCQB: HSEEF)

Hill Incorporated is a progressive bioscience implementation company that is dedicated to building pathways to better and healthier living by leveraging our deep CPG expertise to commercialize leading-edge technologies to craft superior cannabis solutions and non-alcoholic beverage products globally. Our Hill Avenue Cannabis business unit is pioneering the space where craft consumer products meet bioscience by combining our deep CPG commercialization expertise with our rights to use Lexaria Bioscience Corp’s ground-breaking DehydraTECH patent portfolio for product development, licensing and B2B and B2C sales of cannabis ingredients or products on a global scale. Our Hill Street Beverages business unit represents the Company’s legacy alcohol-free consumer beverage marketing and distribution business.

For more information on our business activities visit www.hillincorporated.com, to learn more about our DehydraTECH cannabis biodelivery technology, go to www.dehydratech-thc.com, or to check out Hill Street Beverage’s award-winning alcohol-free wine line-up and order product to be delivered straight to your home, go to www.hillstreetbeverages.com.

If you wish to sign up for the Hill Incorporated mailing list, click HERE.

For more information, contact:

Craig Binkley, Chief Executive Officer

Email: craig@hillincorporated.com

Phone: 604-609-6154

MariMed Company Contact:

Howard Schacter, Chief Communications Officer

Email:  info@marimedinc.com

FORWARD-LOOKING STATEMENTS

Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “would”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Note 1: The Company has reduced its year-over-year trade payables by 66% while maintaining consistent cash reserves.

Note 2: As of Oct 23, 2023, the Company has collected over 80% of its receivables that were outstanding as at June 30, 2023. The remaining 20% is expected to be collected by Nov 30, 2023.

Note 3: As part of the Company’s focused efforts on DehydraTECH expansion in the United States, Hill exited its lease of the Canadian Lucknow cannabis R&D facility in February 2023. This allowed the Company to eliminate under-utilized assets while allocating additional resources to drive additional growth in the US.

Matthew Jewell, CFO, comments: “FY 2023 was a transformational year, both in terms of showing, by way of tremendous operating and financial growth, the potential of our DehydraTECH licensing business and moving on from legacy initiatives and unprofitable business units. The Company’s objectives are now clear, with an executive team that is laser-focused on the key actions to drive the Company towards long term success.”

Shareholder Approval of Hill’s Amended Rolling Stock Option Plan and Amendments to its Restricted Share Unit Plan

Further to the Company’s press release on May 4, 2023, the Company wishes to confirm that at its Annual General and Special Meeting of Shareholders held on May 2, 2023, shareholders of the Company approved (i) the Company’s amended rolling 10% stock option plan; and (ii) certain amendments to the restricted share unit (“RSU”) plan of the Company, which included an increase of the fixed maximum number of RSUs that may be issued by the Company from 175,616 to 323,520 common shares (on a post-share consolidation basis).

In accordance with the TSX’s new policy 4.4 governing security-based compensation plans, certain amendments were made to both the stock option plan and the RSU plan to ensure that the plans met all regulatory requirements. The full text of both plans can be found in the Company’s most recent management information circular, a copy of which can be found on the Corporation’s SEDAR profile at www.sedarplus.ca.

About Hill Incorporated (TSXV: HILL) / (OTCQB: HSEEF)

Hill Incorporated is a progressive bioscience implementation company that is dedicated to building pathways to better and healthier living by leveraging our deep CPG expertise to commercialize leading-edge technologies to craft superior cannabis solutions and non-alcoholic beverage products globally. Our Hill Avenue Cannabis business unit is pioneering the space where craft consumer products meet bioscience by combining our deep CPG commercialization expertise with our rights to use Lexaria Bioscience Corp’s ground-breaking DehydraTECH patent portfolio for product development, licensing and B2B and B2C sales of cannabis ingredients or products on a global scale. Our Hill Street Beverages business unit represents the Company’s legacy alcohol-free consumer beverage marketing and distribution business.

For more information on our business activities visit www.hillincorporated.com, to learn more about our DehydraTECH cannabis biodelivery technology, go to www.dehydratech-thc.com, or to check out Hill Street Beverage’s award-winning alcohol-free wine line-up and order product to be delivered straight to your home, go to www.hillstreetbeverages.com.

If you wish to sign up for the Hill Incorporated mailing list, click HERE.

For more information:

Matthew Jewell, Chief Financial Officer
matthew@hillincorporated.com

604-609-6154

FORWARD-LOOKING STATEMENTS

Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “would”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] US Census Bureau, https://www.census.gov/quickfacts/fact/table/US/PST045221

[2] MJBiz Factbook 2023

[3] MJBiz Factbook 2023

Toronto, ON – TheNewswire – March 1, 2023 – Hill Street Beverage Company Inc. (TSXV:HILL) (OTC:HSEEF) (“Hill Street” or the “Company”), a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally, is pleased to announce the following updates from the three-month period ended December 31, 2022 (“Q2 FY 2023”) financial statements.

Continued DehydraTECH Expansions Lead to Record Quarterly Licensing Revenue & Growth

The Company continued to add states to its geographic footprint for DehydraTECH licensing as well as form factors to its portfolio of DehydraTECH-powered consumer products during the three-month period ended December 31, 2022.

As a result, the Company is pleased to announce that it grew DehydraTECH licensing revenues by 93% in Q2 versus the prior quarter and 263% for the fiscal year to date.

The following chart shows the DehydraTECH licensing revenues over the past 6 quarters:

The Transformed Vin(Zero) Business Model Leads to Record High Quarterly Revenue and Gross Profit

In Q2 FY 2023, Hill Street achieved record quarterly revenues overall and also for its Vin(Zero) alcohol-free beverage business.  The Vin(Zero) results were primarily driven by the Company’s new streamlined Vin(Zero) business model that created a new and different cadence to that business, as we have previously announced.   The Company now executes larger orders that are spread months apart to optimize the timing and efficiency of our supply chain.  The new business model significantly improves key financial metrics such as order to cash and reduced working capital in inventory, but the Vin(Zero) business must now be looked at across longer time frames to truly understand its patterns.

The following chart shows the Vin(Zero) alcohol-free business results over the past 6 quarters:

Release of Q2 FY2023 Financial Statements and MD&A

For the three-month period ended December 31, 2022, the Company has released its Financial Statements, and a comprehensive Company update by way of its Management Discussion and Analysis, which can now be found on the Company’s profile at www.sedar.com.

Craig Binkley, CEO comments: “This was by far the best quarterly result in the Company’s history, for both business units. We are very pleased that our December 31, 2022 results for the Vin(Zero) business validate that the fundamental adjustments we made to our business model over the past several months were well considered and on target.  By refocusing our efforts towards our two on-trend, strong-margin and streamlined business segments – Vin(Zero) beverage sales and DehydraTECH licensing – we are well positioned as we head into the spring.”

Hill Street Mailing List Launched

With the Company expecting increasing shareholder communication over the coming months, Hill Street is pleased to also announce that it has initiated an exclusive mailing list for all supporters wishing to receive direct and timely communication about Company updates.  If you wish to sign up for this mailing list, click HERE.

*All financial information is provided in Canadian dollars, is unaudited and subject to change.

About Hill Street Beverage Company Inc. (TSXV: HILL)

Hill Street is a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally. We are pioneering the space where craft consumer products meet bioscience by leveraging our deep CPG expertise to commercialize leading-edge technologies to craft superior plant-derived consumer products. We are currently developing the platform for North American distribution around our rights to use Lexaria Bioscience Corp.’s ground-breaking DehydraTECH patent portfolio for product development, licensing and B2B sales of cannabis ingredients.

For more information on our business activities or to check out Hill Street’s award-winning alcohol-free line-up and order product to be delivered straight to your home go to www.hillstreetbeverages.com

For more information:

Matthew Jewell, Chief Financial Officer
matthew@hillstreetbevco.com

FORWARD-LOOKING STATEMENTS

Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “would”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• New formulation delivers up to 2,708% more CBD into bloodstream*
• Human clinical hypertension study HYPER-H21-1 also progressing

KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH 2.0″ cannabidiol (“CBD”) formulations in its second 2021 applied research and development study program, HYPER-A21-2.

1. AUC: Area Under the Curve, or total CBD delivery into the rodent bloodstream
2. 60-minute study duration
3. 60-minute study duration evaluated in 2019
4. 120-minute study duration evaluated in 2021

Lexaria continues to build a robust body of evidence demonstrating that its patented DehydraTECH technology can significantly enhance the delivery of lipophilic active ingredients such as CBD across a range of uptake levels, with ultimate applications to wide ranging areas including consumer packaged goods as well as drugs with potential for disease treatment applications.

In each arm of the study, ten male Sprague-Dawley rats were dosed orally at a level of 25 mg/Kg CBD, and over the next 120 minutes multiple measurements were taken to assess delivery into the bloodstream and tissues comparing the DehydraTECH formulations to certain controls. There were a total of 120 animals for the new DehydraTECH 2.0 formulations evaluated in studies HYPER-A21-1 and HYPER-A21-2. Both studies HYPER-A21-1 and HYPER-A21-2 were conducted by an independent, premier animal testing laboratory located in the United States.

Lexaria also confirms that its HYPER-H21-1 human clinical hypertension study is currently underway and dosing is nearly complete, utilizing a formulation most closely resembling the original 2019 DehydraTECH 2.0. Along with a more than a 3-fold increase in dose quantity, these formulation improvements are expected to be more effective than the original DehydraTECH 1.0 formulation used in Lexaria’s foundational 2018 human clinical study that nonetheless evidenced significant blood pressure reduction, as published and available at PubMed. Lexaria thus expects improved pharmacokinetic performance in its current human clinical study to translate into further improved pharmacodynamic performance. Lexaria will provide details on the outcomes of study HYPER-H21-1 when they become available.

* Compared with control formula utilizing medium chain triglycerides (coconut oil) representative of standard industry practices

About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

INVESTOR CONTACT:
[email protected]
Phone: 866-221-3341

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.